Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety frameworks, and implications for national patient protection

Key Points

• To investigate the patterns of gastrointestinal toxicity associated with targeted cancer therapies and their implications for patient safety.
• Analyzed clinicopathologic data related to GI toxicity from targeted cancer therapies.
• Integrated clinical history with pathology for better management.
• Reviewed national surveillance data including FAERS and SEER.
• Identified characteristic pathology patterns of GI toxicity related to cancer therapies.
• Found that enhanced pharmacovigilance improves patient management.
• Emphasized the need for collaboration between pathology and oncology for patient safety.

Abstract